Although epigenetic silencing of the MGMT gene promoter has been associated with prolonged survival in glioblastoma patients[4], there is much controversy about its use as a prognostic marker for the response of patients with newly diagnosed glioblastoma to temozolomide[5,6]. The gene discussed is MGMT; the disease is glioblastoma.